Jaguar Health (JAGX) announced that Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health (FLHLF), completed an import of six kilograms of coca leaf from Peru to Filament’s Metro Vancouver research and development facility. This is the second import of coca leaf into Canada that Magdalena has completed. It was authorized by the Peruvian Health Authority, Direccion General de Medicamentos Insumos y Drogas, and acquired from the Empresa Nacional de la Coca. Dr. King will be presenting more details about the potential promise of whole extract coca leaf Botanical Drugs at The McKenna Academy of Natural Philosophy’s groundbreaking Wisdom of the Leaf Coca Summit, which takes place February 3-7, 2025 in Peru. Magdalena’s mission is to develop novel, safe, efficacious next-generation psychoactive FDA-approved plant-based drugs under FDA Botanical Guidance for mental health indications including schizophrenia, anxiety, depression, and cognitive deficits in attention-deficit/hyperactivity disorder. The coca leaf imported from Peru will be used for the development of a Botanical Drug candidate for the treatment of potentially ADHD or other neuropsychiatric indications.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAGX:
- Jaguar Health’s Napo initiates Phase 2 study to evaluate crofelemer for MVID
- Jaguar Health participates in a conference call with Ladenburg Thalmann
- Jaguar Health granted Orphan Drug designation for crofelemer for diarrhea
- Biotech Alert: Searches spiking for these stocks today
- Jaguar Health announces results of crofelemer for CTD in breast cancer patients